By Hana Lindqvist, MS, RDN, Registered Dietitian Nutritionist. Medically reviewed by Dr. Lila Carter, MD, MPH, Board-Certified Obesity Medicine.
This guide assumes a working baseline. If you're still in week one, the beginner version covers the foundations more slowly. Here, we're getting into the edge cases, the dosing arithmetic, and the questions clinicians actually field at follow-ups.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the Tirzepatide Dosing & Protocols hub.
Key takeaways
- Compounded GLP-1 dosing math: dose in mg divided by concentration in mg/mL equals volume in mL. Multiply volume by 100 to get units on a U-100 syringe.
- The unit count changes any time the pharmacy ships a different concentration, even if the prescribed milligram dose stays the same.
- Standard tirzepatide escalation in SURMOUNT-1: 2.5 mg weekly for 4 weeks, then 5 mg, with 4-weekly step-ups as tolerated.
- Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications for safety, effectiveness, or quality.
Why 880 people a month Google this exact question
Rachel, a 43-year-old insurance adjuster in Omaha, opened her second shipment of compounded tirzepatide and noticed the vial label read 5 mg/mL. Her first vial had been 10 mg/mL. "I almost drew to 25 units again," she told her prescriber at her next telehealth check-in. "If I hadn't read the label twice, I would have injected half my dose." Her prescriber's response: "You're not the first person to catch that, and you're not the last person who almost didn't."
That near-miss is exactly why about 880 monthly U.S. searches land on the phrase "2.5mg to units." The question sounds simple. The answer is simple too, right up until the pharmacy ships a different concentration and the number on the syringe needs to change. A clear written answer has been overdue.
Compounded tirzepatide typically arrives in a vial. The patient draws the dose into a U-100 insulin syringe, the same kind diabetics have used for decades. U-100 means 100 units equals 1 mL of solution. That's the entire conversion framework. Everything else is just plugging in two numbers.
The actual formula (and two worked examples)
The math comes down to two inputs: the concentration printed on your vial and the milligram dose your prescriber wrote. Volume to draw equals prescribed dose divided by concentration. Units on a U-100 syringe equals volume in mL multiplied by 100.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Example 1. Vial concentration is 10 mg/mL. Prescribed dose is 2.5 mg. Volume: 2.5 ÷ 10 = 0.25 mL. On a U-100 syringe, 0.25 mL = 25 units. Draw to the 25-unit mark.
Example 2, different concentration. Vial concentration is 5 mg/mL. Same prescribed 2.5 mg dose. Volume: 2.5 ÷ 5 = 0.5 mL. On a U-100 syringe, 0.5 mL = 50 units. Draw to the 50-unit mark.
Same milligrams. Double the units. That's the whole problem in a nutshell.
The arithmetic is straightforward in isolation. Where things fall apart is the handoff between refills. A different lot number, a different fill volume, sometimes just a different compounding run can mean a different concentration. The unit number that worked last month may correspond to a completely different milligram dose this month. Re-read the label at every fill. Every single one.
Why the escalation starts low (and stays there a while)
The brand-name pen for tirzepatide delivers a fixed dose per click. With compounded vials and a syringe, the patient owns the math. That's more autonomy, but also more room for error, which is why working with a pharmacy that prints concentration clearly on the label matters so much.
The escalation schedule (2.5 mg for four weeks, then 5 mg, then stepwise 4-week jumps) is conservative by design. Most gastrointestinal side effects are dose-dependent and time-limited. Holding at a dose for an extra cycle when nausea is rough isn't failure. It's how the protocol is supposed to work.
Here's the thing most people don't appreciate: the 2.5 mg starting dose isn't really a "therapeutic" dose in the weight-loss sense. It's an onboarding dose. Think of it like the shallow end of the pool. You're there to let your GI tract acclimate, not to see dramatic changes on the scale in week two.
A note on sources
The figures and protocols cited throughout trace back to peer-reviewed publications and FDA prescribing information for the brand-name products. Compounded formulations are not FDA-reviewed, and any practical guidance about compounded products here reflects standard clinical protocol for the underlying active ingredient.
What the trials actually showed
Three trials matter most for context:
SURMOUNT-1 (Jastreboff et al., NEJM 2022) evaluated tirzepatide in adults with obesity without type 2 diabetes over 72 weeks.
SURMOUNT-2 (Garvey et al., Lancet 2023) evaluated tirzepatide in adults with obesity and type 2 diabetes over 72 weeks.
SURMOUNT-4 (Aronne et al., JAMA 2024) evaluated the effect of continued versus withdrawn tirzepatide on weight maintenance.
Trial averages are averages. The data show a wide distribution around the mean, and what a representative trial participant experienced under controlled conditions is not a prediction for any individual outside the trial. That said, the consistency across the SURMOUNT program is pretty striking for an obesity intervention, and the magnitude of effect at higher dose tiers was large enough to reshape how the field thinks about pharmacotherapy for weight management. (My honest take: the SURMOUNT data are the reason GLP-1/GIP agonists crossed from niche endocrinology into mainstream conversation.)
The knobs your prescriber can turn
At a routine follow-up, the clinical options include: hold at current dose, advance to the next step, drop back to the previous step, extend the interval between injections by a day or two, or temporarily pause and resume at a lower step. Each one is a standard move.
Adjustments are not unusual. Roughly half of patients in real-world cohorts hit side effects significant enough to merit a temporary pause or slower escalation at some point in the first six months. That's anticipated. It's baked into the protocol design. If your prescriber slows things down, they're not being overcautious. They're running the play as drawn.
One other detail that sometimes confuses people: reconstitution. That's the step where sterile diluent (usually bacteriostatic water) gets added to a lyophilized powder. Many compounding pharmacies ship pre-mixed vials, which removes this step entirely. If your vial arrives as a liquid, you're already past reconstitution. If it arrives as powder with a separate vial of diluent, your pharmacy should include mixing instructions, and you should follow them exactly.
People who need extra scrutiny before starting
Special populations that change the risk-benefit math: severe renal or hepatic impairment, history of pancreatitis, personal or family history of medullary thyroid carcinoma or MEN2 syndrome (a hard contraindication for GLP-1 receptor agonists), severe gastroparesis, and active gallbladder disease. Any of these can alter the protocol substantially or rule out the medication entirely.
Pregnancy and breastfeeding are not appropriate windows for GLP-1 therapy. Patients planning pregnancy are typically advised to discontinue at least two months before attempting conception, depending on the specific medication.
Patients already on insulin or insulin secretagogues need dose adjustments to those medications when a GLP-1 is added, to reduce hypoglycemia risk. This is a prescriber-led decision. Do not improvise it.
Three myths worth dismantling
"More is better." Above the trial-validated dose range, additional drug doesn't produce a proportional increase in efficacy and often worsens tolerability. The escalation schedule is based on published trial design, not arbitrary caution.
"Side effects mean it's working." Side effects correlate with dose escalation and individual sensitivity, not with the magnitude of weight loss. People with minimal GI symptoms can still lose meaningful weight. People with significant nausea do not necessarily lose more. The two things are surprisingly decoupled.
"It stops working after a few months." Plateaus are a normal part of any weight-loss trajectory and do not equal loss of pharmacologic effect. SURMOUNT-1 and STEP 1 both show continued gradual losses through their 68-to-72-week windows. Most of the absolute change happens in the first half, and the curve flattens, but flattening is not the same as stopping. It's like confusing "the plane leveled off at cruising altitude" with "the engines quit."
What we still don't know
Optimal treatment duration. SURMOUNT-4 and the STEP-4 extension both showed meaningful regain after discontinuation, supporting the view of these medications as chronic therapy. But the truly long-horizon comparative-effectiveness data (five years, ten years) are still maturing.
The GIP question. How exactly does the GIP arm of tirzepatide contribute to the clinical effect, and can selective GIP modulation push outcomes further? Active area of research, no settled answers.
Cardiovascular outcomes beyond weight and A1c. SELECT showed cardiovascular benefit for semaglutide in a defined high-risk population. Comparable long-horizon outcome data for tirzepatide are still accumulating.
Frequently asked questions
Is this something I should discuss with a clinician?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered is worth raising with your prescriber. This article is general education, not a substitute for individualized clinical guidance.
What if I drew the wrong number of units last week?
Stop. Do not inject again and contact your prescriber. If the medication has already been injected at the wrong dose, call the prescriber for guidance. Do not "make up" a dose without explicit instructions.
Does the unit count change if the pharmacy ships a different concentration?
Yes. The unit count is derived from the concentration. A new concentration means a new unit count, even if the milligram dose is the same. Always re-read the label.
Can I use a different syringe than the one the pharmacy provided?
Use only the syringe size and type specified by your pharmacy. A U-100 insulin syringe is standard for the most common compounded GLP-1 concentrations. Substituting a different syringe changes the calibration and is a known source of dosing errors.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
How should I store my compounded tirzepatide vial?
Follow the storage conditions printed on your pharmacy label exactly. Storage outside that range may shorten potency. Discard product that has been frozen or exposed to high heat, and call your pharmacy when in doubt.
What's the difference between the brand-name pen and a compounded vial?
The brand-name pen delivers a fixed dose per injection with no math required. A compounded vial requires you to calculate and draw the correct volume using a syringe. The active ingredient is the same, but the delivery method (and the margin for user error) differs.
Continue the series
Related reading
- Zepbound Injection Site Reaction: Complete Guide
- How to reconstitute 5mg semaglutide?
- 2.5 Mg To Units Syringe: Complete Guide
- Zepbound And Heartburn: Complete Guide
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About this article
Written by Hana Lindqvist, MS, RDN (Registered Dietitian Nutritionist). Medically reviewed by Dr. Lila Carter, MD, MPH (Board-Certified Obesity Medicine). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.